KalVista Pharmaceuticals (KALV) Capital Expenditures Growth (1y) (2015 - 2025)
KalVista Pharmaceuticals (KALV) Capital Expenditures Growth (1y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | 353.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 353.13% |
| Apr 30, 2025 | 168.65% |
| Oct 31, 2024 | 3,150.00% |
| Jul 31, 2024 | 966.67% |
| Apr 30, 2024 | -465.22% |
| Jan 31, 2024 | 1,806.67% |
| Oct 31, 2023 | -98.96% |
| Jul 31, 2023 | -99.35% |
| Apr 30, 2023 | -19.77% |
| Jan 31, 2023 | -92.57% |
| Oct 31, 2022 | -46.07% |
| Jul 31, 2022 | 220.56% |
| Apr 30, 2022 | 160.61% |
| Jan 31, 2022 | 1,342.86% |
| Oct 31, 2021 | 2,638.46% |
| Jul 31, 2021 | 1,204.55% |
| Apr 30, 2021 | 312.50% |
| Oct 31, 2020 | -88.60% |
| Jul 31, 2020 | -77.55% |
| Apr 30, 2020 | -97.09% |